Ebola Vaccines: Biomedical Advances, Human Rights Challenges: Commentary On: A Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein (EBOVGP) Nanoparticle Vaccine with Matrix-M Adjuvant in Healthy Adults

a Phase I trial of an experimental comprising a recombinant Ebola virus glycoprotein nanoparticle as measured by both immunoglobulin G and neutralizing antibody responses. The antibody 2 (days of adjuvanted vaccine, at day 35 and persisting through 1 of the some waning. Nevertheless, based on a pseudovirion neutralization assay, comparatively higher levels of neutralizing elicited from the nanoparticle vaccine of the